The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the use of erythropoietin when used in high dose during acute kidney injury can decrease the number of days of kidney injury.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Clinical Evaluation of the Dose of Erythropoietins Trial

NCT00827021

Kidney Failure, Chronic

COMPLETED PHASE3

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial

NCT00476619

Contrast Induced Nephropathy

TERMINATED PHASE4

Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

NCT03277183

Anemia CKD Atherosclerosis +1 more

TERMINATED PHASE4

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

NCT00367991

Myocardial Infarction

COMPLETED PHASE2

Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity

NCT00744445

Hemodialysis Chronic Renal Failure Anemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute kidney injury is associated with increased morbidity. The most common injury to the kidney occurs during hospitalization with either ischemic or nephrotoxic insult to the kidney. This can prolong hospitalization and depending on the severity of the insult result in permanent decreased kidney function. Recent studies in animals have suggested benefits of using erythropoietin in high doses at time of kidney injury with eividence for less injury in the kidney tissue of those animals who received treatment compared to those animals that received only saline. Limited human data also suggests that use of high dose erythropoietin at the time of stroke can decrease the extent of brain injury. In addition cardiac cell culture studies also have shown decrease in cell injury with use of erythropoietin. These studies have prompted us to evaluate if admininstering erythropoietin to those with onset of acute kidney injury during their hospitalization may benefit from this intervention. This pilot study then evaluates that use of high dose erythropoietin administed daily over 3 days in patients with acute kidney injury on whether the days spent in renal failure are less than those who will receive no study medication. Those patients with kidney failure from either ischemic or nephrotoxic insult and no other contraindication to erythropoietin use will be considered for the study. Informed consent is obtained from the patient or next of kin

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

erythropoeitin

Group Type ACTIVE_COMPARATOR

erythropoietin

Intervention Type DRUG

500 units/kg daily for 3 days at onset of acute kidney injury

2

saline placebo

Group Type PLACEBO_COMPARATOR

saline

Intervention Type DRUG

saline 10 ml for 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erythropoietin

500 units/kg daily for 3 days at onset of acute kidney injury

Intervention Type DRUG

saline

saline 10 ml for 3 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

erythropoeitin normal saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age equal or greater than 21 yo
* acute neprhotoxic or ischemic kidney injury, acute tubular necrosis

Exclusion Criteria

* no active or current malignancies
* not actively receiveing epo
* GFR less than 60 ml/min
* unable to provide informed consent
* contraindication to erythropoietin use

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No